Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Fábio Morato de Oliveira is active.

Publication


Featured researches published by Fábio Morato de Oliveira.


British Journal of Haematology | 2009

Monoclonal B‐cell lymphocytosis in first‐degree relatives of patients with sporadic (non‐familial) chronic lymphocytic leukaemia

Daniel Mazza Matos; Sebastião Ismael; Carlos Alberto Scrideli; Fábio Morato de Oliveira; Eduardo M. Rego; Roberto P. Falcao

Although biological similarities have been described among monoclonal B‐cell lymphocytosis (MBL) and chronic lymphocytic leukaemia (CLL), the relationships between these two conditions are not fully understood, and new epidemiological studies in different populations and different countries continue to be reported. Here, we investigated 167 first‐degree relatives from 42 families of patients with non‐familial (sporadic) CLL, using four‐colour flow cytometry. MBL was found in seven of 167 subjects (4·1%). Monoclonality was detected in all cases either by light‐chain restriction or by polymerase chain reaction. Fluourescence in situ hybridization did not show any chromosomal abnormality. The prevalence of MBL according to age was 0 (0/54) in individuals aged less than 40 years, 2·5% (2/81) between 40 and 60 years, and 15·6% (5/32) in individuals over 60 years. The prevalence of MBL cases in individuals over 60 years was similar to that found in familial CLL relatives at the same age group. This suggests that in older first‐degree relatives of patients with sporadic CLL, the risk of MBL detection is as high as in older first‐degree relatives from CLL families, which could render these individuals belonging to ‘sporadic CLL families’ as susceptible as individuals from ‘familial CLL’ to the development of clinical CLL.


Clinical Cancer Research | 2012

Profiling Three-Dimensional Nuclear Telomeric Architecture of Myelodysplastic Syndromes and Acute Myeloid Leukemia Defines Patient Subgroups

Macoura Gadji; Julius Adebayo Awe; Prerana Rodrigues; Rajat Kumar; Donald S. Houston; Ludger Klewes; Tandakha Ndiaye Dieye; Eduardo M. Rego; Roberto Passetto; Fábio Morato de Oliveira; Sabine Mai

Purpose: Myelodysplastic syndromes (MDS) are a group of disorders characterized by cytopenias, with a propensity for evolution into acute myeloid leukemias (AML). This transformation is driven by genomic instability, but mechanisms remain unknown. Telomere dysfunction might generate genomic instability leading to cytopenias and disease progression. Experimental Design: We undertook a pilot study of 94 patients with MDS (56 patients) and AML (38 patients). The MDS cohort consisted of refractory cytopenia with multilineage dysplasia (32 cases), refractory anemia (12 cases), refractory anemia with excess of blasts (RAEB)1 (8 cases), RAEB2 (1 case), refractory anemia with ring sideroblasts (2 cases), and MDS with isolated del(5q) (1 case). The AML cohort was composed of AML-M4 (12 cases), AML-M2 (10 cases), AML-M5 (5 cases), AML-M0 (5 cases), AML-M1 (2 cases), AML-M4eo (1 case), and AML with multidysplasia-related changes (1 case). Three-dimensional quantitative FISH of telomeres was carried out on nuclei from bone marrow samples and analyzed using TeloView. Results: We defined three-dimensional nuclear telomeric profiles on the basis of telomere numbers, telomeric aggregates, telomere signal intensities, nuclear volumes, and nuclear telomere distribution. Using these parameters, we blindly subdivided the MDS patients into nine subgroups and the AML patients into six subgroups. Each of the parameters showed significant differences between MDS and AML. Combining all parameters revealed significant differences between all subgroups. Three-dimensional telomeric profiles are linked to the evolution of telomere dysfunction, defining a model of progression from MDS to AML. Conclusions: Our results show distinct three-dimensional telomeric profiles specific to patients with MDS and AML that help subgroup patients based on the severity of telomere dysfunction highlighted in the profiles. Clin Cancer Res; 18(12); 3293–304. ©2012 AACR.


Experimental Hematology | 2013

Differential expression of AURKA and AURKB genes in bone marrow stromal mesenchymal cells of myelodysplastic syndrome: correlation with G-banding analysis and FISH.

Fábio Morato de Oliveira; Antonio R. Lucena-Araujo; Maria do Carmo Favarin; Patricia Vianna Bonini Palma; Eduardo M. Rego; Roberto P. Falcao; Dimas Tadeu Covas; Aparecida Maria Fontes

It has been demonstrated that genomic alterations of cells in the hematopoietic microenvironment could induce myelodysplastic syndromes (MDS) with ineffective hematopoiesis and dysmorphic hematopoietic cells, and subsequent transformation to acute myeloid leukemia. This investigation is the first attempt to correlate the gene expression profile of AURKA and AURKB in a cytogenetically stratified population of mesenchymal stem cells (MSCs) from MDS patients. We found that AURKA messenger RNA was expressed at significantly higher levels in MSCs even with normal/altered karyotype when compared with hematopoietic cells and healthy donors. In addition, we found that the presence of chromosomal abnormalities (mainly aneuploidy) in hematopoietic cells/MSCs was also associated with higher levels of AURKA. Different from previous investigations, our findings, regarding AURKA expression support the hypothesis that the presence of chromosomal abnormalities in MSCs from MDS is not a consequence of the method used for chromosome preparation. They may reflect the genomic instability present in the bone marrow microenvironment of MDS patients. This information is also supported by differences observed in the growth kinetics between MSCs from healthy donors (normal karyotype) and from MDS patients with abnormal karyotype. In summary, our results may not be considered evidence that MDS and MSCs are originated from a single neoplastic clone. In fact, both cells (hematopoietic and MSCs) may probably be altered in response to damage-inducing factors, and the presence of genomic abnormalities in MSCs suggests that an unstable bone marrow microenvironment may facilitate the expansion of MDS/leukemic cells.


British Journal of Haematology | 2005

The co-expression of PML/RAR alpha and AML1/ETO fusion genes is associated with ATRA resistance

Rodrigo S. Abreu e Lima; Marcelo R. Baruffi; Ana Silvia G. Lima; Fábio Morato de Oliveira; Lorena Lobo de Figueiredo-Pontes; Luiz Gonzaga Tone; Silvia Regina Rogatto; Roberto P. Falcao; Maria de Lourdes Lopes Ferrari Chauffaille; Eduardo M. Rego

patients are routinely monitored by measuring their serum immunoglobulin and urine light chains – a logical step would be to supplement, or replace, the urine assays with serum FLC measurements, as has already happened in many centres. Thus, the conclusion of Tate et al (2005) that larger prospective studies are needed before FLC measurement is ‘routinely applied to the monitoring of patients with IIMM’, is a generalization, drawn outside the context of the data they have presented. Serial FLC measurement is being undertaken in all patients in the current Medical Research Council Myeloma IX Study, which should provide further information on patients treated in a systematic way. Future studies may investigate clinical benefit further, perhaps with modification or change in treatment determined by FLC measurement.


Blood Cells Molecules and Diseases | 2015

Overexpression of EZH2 associates with a poor prognosis in chronic lymphocytic leukemia.

Doralina do Amaral Rabello; Antonio R. Lucena-Araujo; Juliana Carvalho Rocha Alves-Silva; Vinícius Burnett Aboud Souza da Eira; Maria Catarina Cals de Vasconcellos; Fábio Morato de Oliveira; Eduardo M. Rego; Felipe Saldanha-Araujo; Fabio Pittella Silva

EZH2, a histone methyltransferase, is overexpressed in several human tumors, but whether it exerts any impact in chronic lymphocytic leukemia (CLL) remains unknown. We used real time PCR to investigate the expression profile of EZH1 and EZH2 in 59 CLL patients, 10 samples of purified B-cells from healthy donors and 12 normal adult tissues. EZH2 was overexpressed in CLL patients and correlates with high white blood cell count, ZAP-70 expression and chromosomal abnormalities. EHZ1 expression does not correlate with CLL progression. EZH2 overexpression is related to a poor prognosis of CLL and could be a useful tool to assess its aggressiveness.


Haematologica | 2012

The Aurora A and B kinases are up-regulated in bone marrow-derived chronic lymphocytic leukemia cells and represent potential therapeutic targets

Francisco de Paula Careta; Stefania Gobessi; Rodrigo A. Panepucci; Engin Bojnik; Fábio Morato de Oliveira; Daniel Mazza Matos; Roberto P. Falcao; Luca Laurenti; Marco A. Zago; Dimitar G. Efremov

Background The malignant B cells in chronic lymphocytic leukemia receive signals from the bone marrow and lymph node microenvironments which regulate their survival and proliferation. Characterization of these signals and the pathways that propagate them to the interior of the cell is important for the identification of novel potential targets for therapeutic intervention. Design and Methods We compared the gene expression profiles of chronic lymphocytic leukemia B cells purified from bone marrow and peripheral blood to identify genes that are induced by the bone marrow microenvironment. Two of the differentially expressed genes were further studied in cell culture experiments and in an animal model to determine whether they could represent appropriate therapeutic targets in chronic lymphocytic leukemia. Results Functional classification analysis revealed that the majority of differentially expressed genes belong to gene ontology categories related to cell cycle and mitosis. Significantly up-regulated genes in bone marrow-derived tumor cells included important cell cycle regulators, such as Aurora A and B, survivin and CDK6. Down-regulation of Aurora A and B by RNA interference inhibited proliferation of chronic lymphocytic leukemia-derived cell lines and induced low levels of apoptosis. A similar effect was observed with the Aurora kinase inhibitor VX-680 in primary chronic lymphocytic leukemia cells that were induced to proliferate by CpG-oligonucleotides and interleukin-2. Moreover, VX-680 significantly blocked leukemia growth in a mouse model of chronic lymphocytic leukemia. Conclusions Aurora A and B are up-regulated in proliferating chronic lymphocytic leukemia cells and represent potential therapeutic targets in this disease.


Annals of Hematology | 2010

Results of FLT3 mutation screening and correlations with immunophenotyping in 169 Brazilian patients with acute myeloid leukemia

Antonio R. Lucena-Araujo; Danielle Leão Souza; Fábio Morato de Oliveira; Mariana Tereza de Lira Benício; Lorena Lobo de Figueiredo-Pontes; Barbara A. Santana-Lemos; Guilherme A. dos Santos; Rafael H. Jacomo; Anemari R. Dinarte-Santos; Mihoko Yamamoto; Wilson Araújo Silva-Jr; Maria de Lourdes Lopes Ferrari Chauffaille; Eduardo M. Rego

A. R. Lucena-Araujo :D. L. Souza : F. M. de Oliveira : M. T. L. Benicio : L. L. Figueiredo-Pontes : B. A. Santana-Lemos :G. A. dos Santos : R. H. Jacomo : E. M. Rego (*) Hematology Division, Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, Medical School of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil e-mail: [email protected]


Neuropathology | 2009

Childhood radiation-associated atypical meningioma with novel complex rearrangements involving chromosomes 1 and 12

María Sol Brassesco; Elvis Terci Valera; Luciano Neder; Angel Mauricio Castro-Gamero; Fábio Morato de Oliveira; Antonio Carlos dos Santos; Carlos Alberto Scrideli; Ricardo Santos de Oliveira; Hélio Rubens Machado; Luiz Gonzaga Tone

Meningiomas are recognized as the most common late complication following radiotherapy. However, cytogenetic studies in childhood atypical radiation‐induced meningioma are sporadic, mainly because this condition generally occurs after a long latent period. In the present study we show the results of conventional and molecular cytogenetics in a 14‐year‐old boy with a secondary atypical meningioma. Apart from numerical changes, we found complex aberrations with the participation of chromosomes 1, 6 and 12. The invariable presence of loss of 1p was demonstrated by fluorescent in situ hybridization (FISH) analysis with probes directed to telomeric regions and by comparative genome hybridization (CGH). Previous cytogenetic studies on adult spontaneous and radiation‐associated meningiomas showed loss of chromosome 22 as the most frequent change, followed by loss of the short arm of chromosome 1. To the best of our knowledge this is the first report of highly complex chromosome aberrations in the pediatric setting of meningioma.


Leukemia Research | 2009

New recurrent deletions in the PPARγ and TP53 genes are associated with childhood myelodysplastic syndrome

Cassia G. T. Silveira; Fábio Morato de Oliveira; Elvis Terci Valera; Maura R. V. Ikoma; Tamara Borgonovo; Iglenir João Cavalli; Luiz Gonzaga Tone; Silvia Regina Rogatto

Myelodysplastic syndrome (MDS) is a rare hematological malignancy in children. It was performed FISH analysis in 19 pediatric MDS patients to investigate deletions involving the PPARgamma and TP53 genes. Significant losses in the PPARgamma gene and deletions in the tumor suppressor gene TP53 were observed in 17 and 18 cases, respectively. Using quantitative RT-PCR, it was detected PPARgamma transcript downexpression in a subset of these cases. G-banding analysis revealed 17p deletions in a small number of these cases. One MDS therapy-related patient had neither a loss of PPARgamma nor TP53. These data suggest that the PPARgamma and TP53 genes may be candidates for molecular markers in pediatric MDS, and that these potentially recurrent deletions could contribute to the identification of therapeutic approaches in primary pediatric MDS.


Cancer Genetics and Cytogenetics | 2010

Segmental amplification of MLL gene associated with high expression of AURKA and AURKB genes in a case of acute monoblastic leukemia with complex karyotype

Fábio Morato de Oliveira; Antonio R. Lucena-Araujo; Sabrina Dias Leite-Cueva; Guilherme Augusto S. Santos; Eduardo M. Rego; Roberto Passeto Falcao

We report a case of acute monoblastic leukemia showing a jumping translocation with the MLL gene in a 17-year-old male. Classic cytogenetic and spectral karyotyping revealed a complex karyotype, and fluorescence in situ hybridization (FISH) demonstrated amplification of the MLL gene followed by translocation to chromosomes 15q, 17q, and 19q. In addition, molecular analyses showed a high expression of AURKA and AURKB genes. It is already known that overexpression of Aurora kinases is associated with chromosomal instability and poor prognosis. The formation of jumping translocations is a rare cytogenetic event and there is evidence pointing toward preferential involvement of the heterochromatin region of donor chromosomes and the telomere ends of recipient chromosomes. Jumping translocation with the MLL gene rearrangement is an uncommon phenomenon reported in leukemia cytogenetics.

Collaboration


Dive into the Fábio Morato de Oliveira's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Antonio R. Lucena-Araujo

Federal University of Pernambuco

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge